Biohaven’s Zavegepant Aims to Expand CGRP Migraine Treatment Options

NeurologyLiveJune 2021
Volume 4
Issue 3

After showing early success, zavegepant eyes a pivotal phase 2/3 trial with potential regulatory submission around the corner.

Elyse Stock, MD, chief medical officer, Biohaven

Elyse Stock, MD

AS THE MIGRAINE TREATMENT TOOLBOX has expanded in recent years, the most notable option has been the introduction of the calcitonin gene-related peptide (CGRP) inhibitors. Biohaven’s third-generation, highly soluble small molecule zavegepant may be next to join that list of therapies.

In early April, the company announced that the first patient in a phase 2/3 clinical trial (NCT04804033) had been dosed with oral zavegepant.1 The pivotal double-blind, placebo-controlled study will enroll approximately 2900 participants to evaluate the safety and efficacy of 100-mg and 200-mg zavegepant over a 12-week study period.

“It is designed to be able to provide the FDA with what it will require for approval if we are ultimately successful,” Elyse Stock, MD, chief medical officer, Biohaven, told NeurologyLive®.

The primary end point of the study is mean reduction from baseline in the number of monthly migraine days, during weeks 9 to 12. Secondary end points included are the proportion of subjects achieving greater than or equal to 50% reduction from baseline in moderate to severe headache days, as well as safety and tolerability of zavegepant (FIGURE).

Stock noted that the company hopes to complete the study in the second half of 2022 and did not anticipate any interim data readouts. Rimegepant (Nurtec ODT), which was approved in February 2020 for the acute treatment of migraine in adult patients, was Biohaven’s first approved migraine medication and was crucial in better constructing the zavegepant clinical trial process.2

FIGURE. Phase 2/3 Trial of Zavegepant in Migraine

FIGURE. Phase 2/3 Trial of Zavegepant in Migraine

“The whole clinical trial process with rimegepant made this easier. There clearly is some guidance that we, and others, have gotten from the regulatory agencies across the globe on how to run these programs so that, if we’re successful and have a positive study, we get an approval,” Stock said.

Rimegepant, another CGRP-targeted treatment, was granted approval based on the results from 2 clinical trials: the phase 3 Study 303 (NCT03461757) and the long-term, open-label safety trial, Study 201 (NCT03266588). In its clinical development, more than 3100 patients were treated with more than 113,000 doses of the therapy.

As for zavegepant, Biohaven announced topline results from another phase 2/3 clinical trial (BHV3500-201; NCT03872453) evaluating the efficacy and tolerability of its intranasal form in 5-mg, 10-mg, and 20-mg doses vs placebo in 1673 patients for the acute treatment of migraine. At 2 hours, treatment with a single dose of zavegepant 10 mg or 20 mg showed statistically superior results to placebo on the coprimary end points of pain freedom and freedom from the most bothersome symptom (MBS; photophobia, phonophobia, or nausea).3

The drug also demonstrated a duration and sustained effect profile through 48 hours (nominal P <.05). This included sustained pain freedom 2 to 24 hours (5 mg, 10 mg, and 20 mg), sustained pain freedom 2 to 48 hours (5 mg, 10 mg, and 20 mg), sustained pain relief 2 to 24 hours (5 mg, 10 mg, and 20 mg), and sustained pain relief 2 to 48 hours (5 and 10 mg).

Across a number of secondary end points, the treatment continued to show its early activity (nominal P <.05). The treatment also had rapid onset with pain relief at 15 minutes (10 and 20 mg), with patients returning to normal function as early as 30 minutes in the 20-mg dose group. Therapeutic benefits on both pain relief and return to normal function at 2 hours were observed in both the 10-mg and 20-mg dose groups.

Zavegepant, which was known at the time as vazegepant, eventually had its named revised by the World Health Organization and was accepted by the United States Adopted Names (USAN) Council for use in the US.

Stock noted that there are a number of benefits that both oral and intranasal zavegepant can bring to patients. Discussing intranasal zavegepant, she told NeurologyLive®, “It may be more appropriate for someone who is getting a migraine all of a sudden and will need something that they will rapidly respond to and where they don’t want to take anything by mouth at all.”

She said there are a number of other disorders outside the migraine space that could benefit from CGRP. She explained that the company is looking into respiratory, dermatologic, and infectious disease spaces. Biohaven currently has ongoing studies involving patients with COVID-19 as well as psoriasis and is planning to start another that will include patients with asthma.

1. Biohaven enrolls first patient in phase 2/3 trial of oral zavegepant, prompting $100 million milestone funding payment from Royalty Pharma. News release. March 29, 2021. Accessed April 28, 2021.
2. Biohaven’s Nurtec ODT (rimegepant) receives FDA approval for the acute treatment of migraine in adults. News release. Biohaven. February 27, 2020. Accessed April 29, 2021.
3. Biohaven achieves positive topline results in pivotal phase 2/3 study of vazegepant, the first and only intranasal CGRP receptor antagonist in clinical development for the acute treatment of migraine. News release. December 17, 2019. Accessed April 2, 2021.
Related Videos
Video 2 - 4 KOLs are feature in, "Changes in Presentation of Spasticity Over Time"
Video 1 - 4 KOLs are feature in, "Definition and Pathophysiology of Spasticity"
Dolores D. Santamaria, MD
 Bruce Cree, MD, PhD, MAS, FAAN
Video 3 - 5 KOLs are featured in "Transitions of Care: Moving Spinal Muscular Atrophy Patients from Pediatric/Adolescent Care to Adult Clinics"
Video 3 - 5 KOLs are featured in "Presentation of Adult Spinal Muscular Atrophy in Clinics"
Fawad Khan, MD, FACNS
Valerie J. Block, PT, DPTSc
© 2024 MJH Life Sciences

All rights reserved.